Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds

PDF File ACRX Corporate Presentation - 11/7/14

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. AcelRx has announced positive results from each of the three Phase 3 clinical trials for Zalviso and has submitted an NDA to the FDA seeking its approval. AcelRx also announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from U.S. Army Medical Research and Materiel Command. The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.
ACRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$6.69
Change (%) Stock is Up 0.30 (4.69%)
Volume780,556
Data as of 12/19/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

    More >>
12/02/14AcelRx Pharmaceuticals Receives CE Mark Approval for Zalviso
REDWOOD CITY, Calif., Dec. 2, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark approval (Conformite Europeenne) for the Zalviso device. Zalviso is a drug-device combination product utilizing the opioid agonist sufentanil formulated in a proprietary sublingual tablet formulation an... 
Printer Friendly Version
11/20/14AcelRx Pharmaceuticals to Participate in Four Upcoming Investor Events
REDWOOD CITY, Calif., Nov. 20, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will be participating at Piper Jaffray, RBC, Guggenheim and Roth Healthcare Conferences. Details of the events are as follows: Piper Jaffray Healthcare Conference 2014 Date: Tuesday, December 2nd Locat... 
Printer Friendly Version
11/13/14AcelRx Pharmaceuticals Announces Zalviso™ Sublingual Sufentanil Data Presentation At The American Society Of Regional Anesthesia And Pain Medicine Meeting
Data from Sublingual Sufentanil Tablet System Development Program Highlights Efficacy across Various Demographic Populations REDWOOD CITY, Calif., Nov. 13, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that a moderated poster presentation will be made at the American Society of Regional Anesthesia and P... 
Printer Friendly Version

Upcoming Events

    More >>
There are currently no events scheduled.

Receive E-mail Alerts 

Sign up to receive e-mail alerts whenever AcelRx Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

AcelRX

CONTACT